Mechanisms underlying the inhibitory effects of arsenic compounds on protein tyrosine phosphatase (PTP)

Toxicology and Applied Pharmacology

Volumn 263, Issue 3, 2012, Pages 273-280

  Rehman, Kanwal ^a   Chen, Zhe ^b   Wang, Wen Wen ^a   Wang, Yan Wei ^a   Sakamoto, Akira ^c   Zhang, Yan Fang ^a   Naranmandura, Hua ^a   Suzuki, Noriyuki ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Arsenic; Arsenite; Cancer; CD45; Dimethylarsinous acid; Monomethylarsonous acid; Protein tyrosine phosphatase; Reactive oxygen species

Indexed keywords

ARSENIC; ARSENIC TRIOXIDE; CD45 ANTIGEN; CYSTEINE; DIMETHYLARSINOUS ACID; DITHIOTHREITOL; INORGANIC COMPOUND; MONOMETHYLARSONOUS ACID; PROTEIN TYROSINE PHOSPHATASE 1B; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; FRAGMENTATION REACTION; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHYLATION;

ANTIGENS, CD45; ARSENITES; BINDING SITES; CACODYLIC ACID; HEP G2 CELLS; HUMANS; ORGANOMETALLIC COMPOUNDS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PROTEIN TYROSINE PHOSPHATASES; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84865428014     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.06.019     Document Type: Article

References (36)

1. Ahn R.W., Chen F., Chen H., Stern S.T., Clogston J.D., Patri A.K., Raja M.R., Swindell E.P., Parimi V., Cryns V.L., O'Halloran T.V. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin. Cancer Res. 2010, 16:3607-3617.
2. Andersen J.N., Mortensen O.H., Peters G.H., Drake P.G., Iversen L.F., Olsen O.H., Jansen P.G., Andersen H.S., Tonks N.K., Moller N.P. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell. Biol. 2001, 21:7117.
3. Barford D., Jia Z., Tonks N.K. Protein tyrosine phosphatases take off. Nat. Struct. Biol. 1995, 2:1043-1053.
4. Bode A.M., Dong Z.G. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit. Rev. Oncol. Hematol. 2002, 42:5-24.
5. Douer D., Tallman M.S. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J. Clin. Oncol. 2005, 23:2396-2410.
6. Giles N.M., Watts A.B., Giles G.I., Fry F.H., Littlechild J.A., Jacob C. Metal and redox modulation of cysteine protein function. Chem. Biol. 2003, 10:677-693.
7. Haase H., Maret W. Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants. Biometals 2005, 18:333-338.
8. Hunter T. Signaling-2000 and beyond. Cell 2000, 100:113-127.
9. Iwamoto N., Sumi D., Ishii T., Uchida K., Cho A.K., Froines J.R., Kumagai Y. Chemical knockdown of protein-tyrosine phosphatase 1B by 1,2-naphthoquinone through covalent modification causes persistent transactivation of epidermal growth factor receptor. J. Biol. Chem. 2007, 282:33396-33404.
10. Jiang G., Gong Z., Li X.F., Cullen W.R., Le X.C. Interaction of trivalent arsenicals with metallothionein. Chem. Res. Toxicol. 2003, 16:873-880.
11. Lee S.R., Kwon K.S., Kim S.R., Rhee S.G. Reversible inactivation of protein tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J. Biol. Chem. 1998, 273:15366-15372.
12. Lessard L., Stuible M., Tremblay M.L. The two faces of PTP1B in cancer. Biochim. Biophys. Acta 2010, 1804:613-619.
13. Li L., Dixon J.E. Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases. Semin. Immunol. 2000, 12:75-84.
14. Lin S., Cullen W.R., Thomas D.J. Methylarsenicals and arsenothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem. Res. Toxicol. 1999, 12:924-930.
15. Lu M., Wang H., Li X.F., Lu X., Cullen W.R., Arnold L.L., Cohen S.M., Le X.C. Evidence of hemoglobin binding to arsenic as a basis for the accumulation of arsenic in rat blood. Chem. Res. Toxicol. 2004, 17:1733-1742.
16. Lu J., Chew E.H., Holmgren A. Targeting thioredoxin reductase is basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12288-12293.
17. Lu M., Wang H., Wang Z., Li X.F., Le X.C. Identification of reactive cysteines in a protein using arsenic labeling and collision-induced dissociation tandem mass spectrometry. Proteome Res. 2008, 7:3080-3090.
18. Meng T.C., Lou Y.W., Chen Y.Y., Hsu S.F., Huang Y.F. Cys-oxidation of protein tyrosine phosphatases: its role in regulation of signal transduction and its involvement in human cancers. J. Cancer Mol. 2006, 2:9-16.
19. Naranmandura H., Suzuki K.T. Identification of the major arsenic-binding protein in rat plasma as the ternary dimethylarsinous-hemoglobin-haptoglobin complex. Chem. Res. Toxicol. 2008, 21:678-685.
20. Naranmandura H., Xu S., Sawada T., Hao W., Liu H., Bu N., Ogra Y., Lou Y., Suzuki N. Mitochondria are the main target organelle for trivalent monomethylarsonous acid (MMAIII)-induced cytotoxicity. Chem. Res. Toxicol. 2011, 24:1094-1103.
21. Naranmandura H., Xu S., Koike S., Pan L., Chen B., Wang Y., Rehman K., Wu B., Chen Z., Suzuki N. The endoplasmic reticulum is a target organelle for trivalent dimethylarsinic acid (DMAIII)-induced cytotoxicity. Toxicol. Appl. Pharmacol. 2012, 260:241-249.
22. National Research Council Arsenic in Drinking Water 1999, National Academy Press, Washington, D. C.
23. National Research Council Arsenic in Drinking Water 2001 Update 2001, National Academy Press, Washington, D. C.
24. Neel B.G., Tonks N.K. Protein tyrosine phosphatases in signal transduction. Curr. Opin. Cell Biol. 1997, 9:193-204.
25. Ostman A., Böhmer F.D. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol. 2001, 6:258-266.
26. Petrick J.S., Bhumasamudram J., Mash E.A., Aposhian H.V. Monomethylarsonous acid (MMA III ) and arsenite: LD 50 in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem. Res. Toxicol. 2001, 14:651-656.
27. Rehman K., Naranmandura H. Arsenic metabolism and thioarsenicals. Metallomics 2012, 10.1039/C2MT00181K.
28. Seiner D.R., LaButti J.N., Gates K.S. Kinetics and mechanism of protein tyrosine phosphatase 1B (PTP1B) inactivation by acrolein. Chem. Res. Toxicol. 2007, 20:1315-1320.
29. Styblo M., Thomas D.J. Binding of arsenicals to proteins in an in vitro methylation system. Toxicol. Appl. Pharmacol. 1997, 147:1-8.
30. Styblo M., Serves S.V., Cullen W.R., Thomas D.J. Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem. Res. Toxicol. 1997, 10:27-33.
31. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203-212.
32. Verma A., Mohindru M., Deb D.K., Sassano A., Kambhampati S., Ravandi F., Minucci S., Kalvakolanu D.V., Platanias L.C. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J. Biol. Chem. 2002, 277:44988-44995.
33. Wang Z., Zhang H., Li X.F., Le X.C. Study of interactions between arsenicals and thioredoxins (human and E. coli) using mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21:3658-3666.
34. Wang Q., Lu L., Yuan C., Pei K., Liu Z., Guo M., Zhu M. Potent inhibition of protein tyrosine phosphatase 1B by copper complexes: implications for copper toxicity in biological systems. Chem. Commun. 2010, 46:3547-3549.
35. Zhang Z.Y. Protein tyrosine phosphatases: structure and function, substrate specificity and inhibitor development. Annu. Rev. Pharmacol. Toxicol. 2002, 42:209-234.
36. Zhang Z.Y. Chemical and mechanistic approaches to the study of protein tyrosine phosphatases. Acc. Chem. Res. 2003, 36:385-392.